RNA Modulation Technology
Amylon’s drug development platform is based on our innovative RNA Modulation Technology. RNA Modulation Technology uses antisense oligonucleotides (ASOs) to alter the splicing of pre-mRNA to counteract the effects of disease-causing mutations.
Amylon Therapeutics is a biotechnology company dedicated to developing therapies for rare genetic disorders of the central nervous system. Amylon is led by a strong management team of entrepreneurs and industry veterans, complemented by a world-class supervisory- and scientific advisory board.
Amylon has several therapeutic programs in its pipeline. Our lead research program targets the disorder Hereditary Cerebral Hemorrhage with Amyloidosis Dutch Type (HCHWA-D), also referred to as Katwijk’s disease, the most common form of hereditary cerebral amyloid angiopathy (CAA).
Deliver on the potential of our RNA Modulation Technology by developing life-changing therapeutic solutions for patients with serious unmet medical need.
Amylon appoints Art Levin to supervisory board; expands scientific advisory board
Cambridge, Massachusetts, January 17th 2019 Amylon Therapeutics, a biotechnology company using RNA modulation to target neurological disorders, announces the appointment of Art Levin as its new supervisory board member, as well as the expansion of its scientific...
Dan Curtis joins Amylon Therapeutics as Chief Development Officer
Cambridge, Massachusetts, 26 June 2018 Amylon Therapeutics, a biotechnology company using an ultragenetics approach towards neurological disorders, announces the appointment of Daniel Curtis PhD as its new Chief Development Officer. In his role, Dan will be...